{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-001472","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2026-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.677519+00:00","generated_at":"2026-05-16T11:43:15.719579+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026","bullets":["NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026","Navacaprant KOASTAL-2 and -3 joint readout in Q2 2026; enrollment increased up to 25% beyond original target of 332","NMRA-215 Phase 1 for obesity to initiate H1 2026; weight loss data expected around end of 2026","Cash, cash equivalents and marketable securities support operations into Q3 2027; M4 PAM franchise update mid-2026"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-001472","json":"https://secwatch.observer/filing/0001193125-26-001472.json","markdown":"https://secwatch.observer/filing/0001193125-26-001472.md","text":"https://secwatch.observer/filing/0001193125-26-001472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526001472/0001193125-26-001472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526001472/d33765d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:43:15.719579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}